Kaposi's sarcoma after liver transplantation

J Cancer Res Clin Oncol. 2008 Jun;134(6):653-8. doi: 10.1007/s00432-007-0329-3. Epub 2007 Oct 9.

Abstract

Introduction: Kaposi's Sarcoma (KS) is a malignant neoplasm arising from endothelial cells. HHV8-infection represents a key pathogenic determinant for the development of KS. There are no standard criteria to treat KS in immunosuppressed-individuals. Six cases (2.1%) of KS occurred in our Center among 285-recipients who underwent liver transplantation (LT) between October 2000 and November 2006.

Methods: Patients were four males and two females. Mean age was 57 years (range 44-65). Indication for LT was ESLD associated/non-associated with hepatocellular carcinoma (HCC). The immunosuppressive regimen consisted of cyclosporine/tacrolimus associated with steroids or daclizumab. HHV8-detection was performed by the serological method before LT, and by polymerase chain reaction (PCR)-analysis after KS.

Results: One patient had HCV-related cirrhosis and coinfection from HIV, three had HBV-related cirrhosis, two of these with coexistent HCC. The last two patients had alcoholic-cirrhosis, one with coexistent HCC. Mean time from transplantation to KS was 6.2 months (range 3.8-8.8). Three patients were treated with doxorubicin and three with switch from calcineurin-inhibitors to sirolimus. Three patients expired after 11.5, 8.8, and 7.4 months from KS diagnosis.

Discussion: KS should be treated by a multidisciplinary approach to obtain an early diagnosis and best management. Effective treatment with immunosuppression reduction or switch to sirolimus is mandatory and can induce complete regression.

MeSH terms

  • Adult
  • Aged
  • Cyclosporine / therapeutic use
  • Female
  • Herpesvirus 8, Human / isolation & purification
  • Humans
  • Liver Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Sarcoma, Kaposi / etiology*
  • Sarcoma, Kaposi / therapy

Substances

  • Cyclosporine